

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

ORPHAN MEDICAL INC

Form 8-K

June 12, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2003

ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware -----	0-24760 -----	41-1784594 -----
(State or other jurisdiction of incorporation) number)	(Commission file number)	(I.R.S. employer identification
Suite 250, 13911 Ridgedale Drive, Minnetonka, MN -----	55305 -----	(952) 513-6900 -----
(Address of principal executive offices)	(zip code)	(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Item 2. Acquisition or Disposition of Assets.

The Company completed the sale of Busulfex(R) (busulfan) Injection on June 10, 2003. The Company received \$29.5 million of cash proceeds from the transaction.

Item 7. Financial Statements and Exhibits

(b) Pro forma financial statements will be provided.

Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

Item 9. Regulation SD Disclosure

The Company's sale of Busulfex(R) was discussed in the Company's press release dated June 10, 2003. The press release is attached as Exhibit 99.1 to this Form 8-K.

Exhibit List

Exhibit 99.1 - Press release dated June 10, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 12, 2003

ORPHAN MEDICAL, INC.

/s/ Timothy G. McGrath

Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated June 10, 2003